Dr Bernd Eisele | Chief Executive Officer
Vakzine Projekt Management Gmbh

Dr Bernd Eisele, Chief Executive Officer, Vakzine Projekt Management Gmbh

Bernd Eisele M.D. is CEO since 2008 and Chief Medical Officer of VPM since 2003. From 1997-2002 he was Medical Director and Head of Medical Marketing of Region 6 in Solvay Pharmaceuticals GmbH, Hannover. Region 6 comprised Canada, Asia, the Middle East, India, Australia, and South Africa. Bernd was responsible for the planning and conduct of local and region-wide marketing campaigns for Solvay’s influenca vaccine and for its cardiovascular, gastroenterology, gynecology, and psychiatry products.

Additionally, Bernd planned and supervised the company’s pivotal trials within the Region which were needed for local registrations (e.g., for PR China). In 2002, he was appointed Global Product Director for psychiatry and became responsible for the world-wide marketing of Solvay Pharmaceuticals’ psychiatry products. Bernd had joined Solvay in 1996 and was responsible for the international phase III development program of one of Solvay´s leading cardiovascular products.

Bernd Eisele began his career in the industry as a Clinical Project Manager at Behringwerke AG in 1988. In various positions Bernd was responsible for the clinical development of recombinant and transgenic products in clinical phases I – III.

Bernd Eisele holds a doctorate in medicine from Heidelberg Medical University (1986).


Day Three 12th October, Human @ 09:40

VPM1002: A recombinant BCG as a novel infant and post-exposure adult tuberuclosis vaccine

back to speakers